Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class

Executive Summary

Safety and efficacy of what would be sixth GLP-1 agonist seem solid, but FDA advisory committee notes concerns about allergic reactions, dosing and relative effectiveness.

You may also be interested in...



Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

The latest drug development news and highlights from our FDA Performance Tracker.

Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments

After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.

Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros

The latest drug development news and highlights from our FDA Performance Tracker

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel